MentalHealthDaily

Psilocybin for Depression: Optimal Dosages for Antidepressant Effects (2023 Review)

by GLOOM

Recent research has provided compelling evidence on the therapeutic potential of psilocybin, a naturally occurring psychedelic, in treating depression. A systematic review and dose-response meta-analysis shed light on the optimal dosage of psilocybin for depression, revealing variations in effectiveness based on patient subgroups and associated risks. Highlights: Psilocybin showed significant antidepressant effects, with optimal dosages …

Olanzapine for Anorexia: A Promising Treatment Both Systemically & Intranasally (2023 Study)

by GLOOM

Anorexia nervosa (AN), a severe mental disorder characterized by an intense fear of gaining weight and a distorted body image, remains a formidable challenge in psychiatric treatment. Recent research has shone a light on the potential of olanzapine, an atypical antipsychotic, in offering new hope through both systemic and innovative intranasal administration methods in animal …

Quetiapine-Induced Psychosis: A Rare Adverse Effect (2024 Case Report)

by GLOOM

Quetiapine, a second-generation antipsychotic medication, is renowned for its efficacy in managing a spectrum of psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder (MDD). Despite its broad therapeutic utility and a generally favorable side effect profile, quetiapine’s role in rare instances of inducing psychotic symptoms warrants a closer examination. Highlights: Quetiapine’s Mechanism of …

Gene Editing with CRISPR/Cas9 to Treat Corticosteroid-Induced Neuropsychiatric Disorders (2023 Review)

by GLOOM

The widespread use of corticosteroids (CCSs) across the globe for treating inflammatory conditions has led to an increased incidence of corticosteroid-induced neuropsychiatric disorders (NPDs), raising significant public health concerns. These disorders range from depression and anxiety to severe cognitive changes, challenging the medical community to find effective treatments. The exploration of genetic and epigenetic factors …

GW043 as Rapid Antidepressant: Partial Agonist of NMDA Receptors (2024 Study)

by GLOOM

GW043 emerges as a promising new compound in the treatment of depression showcasing rapid and significant antidepressant effects by targeting NMDA receptors (NMDARs). This mechanism offers hope for those suffering from depression and sheds light on the intricate mechanisms of synaptic plasticity and neurogenesis that underpin GW043’s therapeutic benefits. Highlights: GW043’s Mechanism of Action: GW043 …

Lactofem Probiotic as Adjunct to SSRI Antidepressants May Enhance Mood & Sexual Satisfaction in Women (2024 Study)

by GLOOM

The link between mental health and sexual function is complex and multifaceted, with depressive disorders particularly affecting individuals’ sexual satisfaction and functionality. Recent research has highlighted the potential benefits of probiotics in mitigating these impacts, especially among women undergoing treatment with Selective Serotonin Reuptake Inhibitors (SSRIs). A new study conducted in Iran provides promising evidence …

Lisdexamfetamine (Vyvanse) Changes Brain Connectivity & Activation to Treat Binge Eating Disorder (2023 Study)

by GLOOM

Binge-eating disorder (BED), characterized by recurrent episodes of overeating without compensatory behaviors, is a significant global health concern. Lisdexamfetamine dimesylate (LDX), the only drug approved for moderate to severe BED, is showing promise not just in reducing episodes but also in altering brain function in ways previously not fully understood. Through a groundbreaking study, researchers …